Development and targeted use of nilotinib in chronic myeloid leukemia
Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CM...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2008-11-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | http://www.dovepress.com/development-and-targeted-use-of-nilotinib-in-chronic-myeloid-leukemia-a2556 |